Thromboembolic disorders are among the major causes of morbidity and mortality, and
anticoagulation remains the cornerstone of prevention and treatment of these disorders …

Anticoagulant drugs have an essential role in the prevention and treatment of
thromboembolic diseases. Currently available anticoagulants substantially reduce the …

Background Novel oral anticoagulants are approved in several indications: rivaroxaban,
apixaban, and dabigatran for the prevention of venous thromboembolism after elective hip …

Thromboembolic diseases are common. Heparins and the vitamin K antagonists have been
the mainstay of therapy for> 60 years, but both classes of agents have limitations. The “ideal” …

In recent years, several direct‐acting oral anticoagulants (DOAC) have become available for
use in Europe and other regions in indications related to prophylaxis and treatment of …

Until recently, warfarin had been one of the only treatment options for long-term
anticoagulation of patients with atrial fibrillation, venous thromboembolism, or other medical …

Dabigatran (a direct thrombin inhibitor) and rivaroxaban, apixaban, and edoxaban (direct
activated factor X inhibitors) are increasingly being used in clinical practice. Compared with …

Venous thromboembolism (VTE) is a major cause of morbidity, mortality, and healthcare
expenditure. In the United States, approximately 0.1% of the population experiences an …

Oral anticoagulation therapy is transforming with the advent of the target specific oral
anticoagulants, particularly, the direct thrombin inhibitors and factor Xa inhibitors. These …

While parenteral anticoagulants such as unfractionated and low molecular weight heparins
and the oral vitamin K antagonists are effective for the prevention and treatment of …